About: Lexatumumab

Property	Value
dbo:abstract	لكساتوموماب جسم مضاد وحيد النسيلة بشري تجري عليه التجارب السريرية لاستخدامه في علاج السرطان. (ar) Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2), intended for the treatment of cancer. HGS-ETR2 antibodies were generated by Human Genome Sciences through a collaboration with Cambridge Antibody Technology. Development was discontinued in 2015. (en) Il lexatumumab o ETR2-ST01, è un anticorpo monoclonale di tipo umano, che viene studiato per il trattamento di forme di tumore. Esso è stato sviluppato dalla , Inc.. Il farmaco agisce sull'antigene: -R2. (it)
dbo:casNumber	845816-02-6
dbo:fdaUniiCode	967Q0SJD77
dbo:kegg	D06611
dbo:wikiPageID	9700526 (xsd:integer)
dbo:wikiPageLength	2767 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1058530797 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Cambridge_Antibody_Technology dbr:Cancer dbr:Human dbr:Human_Genome_Sciences dbr:Monoclonal_antibody dbc:Experimental_cancer_drugs dbc:Monoclonal_antibodies_for_tumors dbr:TRAIL-R2
dbp:atcPrefix	none (en)
dbp:c	6346 (xsd:integer)
dbp:casNumber	845816 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:h	9832 (xsd:integer)
dbp:kegg	D06611 (en)
dbp:mabType	mab (en)
dbp:n	1720 (xsd:integer)
dbp:o	2002 (xsd:integer)
dbp:s	42 (xsd:integer)
dbp:source	u (en)
dbp:target	TRAIL-R2 (en)
dbp:type	mab (en)
dbp:unii	967 (xsd:integer)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	458270193 (xsd:integer)
dbp:watchedfields	changed (en)
dbp:wikiPageUsesTemplate	dbt:Antineoplastic-drug-stub dbt:Drugbox dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Keggcite dbt:Monoclonal-antibody-stub dbt:Monoclonals_for_tumors
dcterms:subject	dbc:Experimental_cancer_drugs dbc:Monoclonal_antibodies_for_tumors
gold:hypernym	dbr:Antibody
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:WikicatMonoclonalAntibodiesForTumors yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459 umbel-rc:DrugProduct
rdfs:comment	لكساتوموماب جسم مضاد وحيد النسيلة بشري تجري عليه التجارب السريرية لاستخدامه في علاج السرطان. (ar) Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2), intended for the treatment of cancer. HGS-ETR2 antibodies were generated by Human Genome Sciences through a collaboration with Cambridge Antibody Technology. Development was discontinued in 2015. (en) Il lexatumumab o ETR2-ST01, è un anticorpo monoclonale di tipo umano, che viene studiato per il trattamento di forme di tumore. Esso è stato sviluppato dalla , Inc.. Il farmaco agisce sull'antigene: -R2. (it)
rdfs:label	لكساتوموماب (ar) Lexatumumab (it) Lexatumumab (en)
owl:sameAs	freebase:Lexatumumab wikidata:Lexatumumab dbpedia-ar:Lexatumumab dbpedia-it:Lexatumumab https://global.dbpedia.org/id/BWdQ yago-res:Lexatumumab
prov:wasDerivedFrom	wikipedia-en:Lexatumumab?oldid=1058530797&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Lexatumumab
is dbo:wikiPageRedirects of	dbr:Lexitumumab
is dbo:wikiPageWikiLink of	dbr:Cambridge_Antibody_Technology dbr:Human_Genome_Sciences dbr:Mapatumumab dbr:List_of_therapeutic_monoclonal_antibodies dbr:List_of_drugs:_Le dbr:Lexitumumab
is foaf:primaryTopic of	wikipedia-en:Lexatumumab